- Home
- CODI vs NGNE Comparison
CODI vs NGNE Comparison
Compare CODI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODI
- NGNE
- Stock Information
- Founded
- CODI 2005
- NGNE 2003
- Country
- CODI United States
- NGNE United States
- Employees
- CODI N/A
- NGNE N/A
- Industry
- CODI Home Furnishings
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- CODI Consumer Discretionary
- NGNE Health Care
- Exchange
- CODI Nasdaq
- NGNE Nasdaq
- Market Cap
- CODI 480.0M
- NGNE 426.6M
- IPO Year
- CODI 2006
- NGNE N/A
- Fundamental
- Price
- CODI $5.89
- NGNE $20.10
- Analyst Decision
- CODI Buy
- NGNE Strong Buy
- Analyst Count
- CODI 2
- NGNE 6
- Target Price
- CODI $26.00
- NGNE $38.50
- AVG Volume (30 Days)
- CODI 1.4M
- NGNE 293.9K
- Earning Date
- CODI 10-29-2025
- NGNE 11-13-2025
- Dividend Yield
- CODI 16.56%
- NGNE N/A
- EPS Growth
- CODI N/A
- NGNE N/A
- EPS
- CODI N/A
- NGNE N/A
- Revenue
- CODI $2,198,233,000.00
- NGNE N/A
- Revenue This Year
- CODI $15.09
- NGNE N/A
- Revenue Next Year
- CODI $8.26
- NGNE N/A
- P/E Ratio
- CODI N/A
- NGNE N/A
- Revenue Growth
- CODI 11.87
- NGNE N/A
- 52 Week Low
- CODI $5.30
- NGNE $6.88
- 52 Week High
- CODI $24.32
- NGNE $37.27
- Technical
- Relative Strength Index (RSI)
- CODI 45.05
- NGNE 36.16
- Support Level
- CODI $5.33
- NGNE $19.68
- Resistance Level
- CODI $6.05
- NGNE $22.42
- Average True Range (ATR)
- CODI 0.40
- NGNE 2.70
- MACD
- CODI 0.03
- NGNE -1.14
- Stochastic Oscillator
- CODI 51.20
- NGNE 7.70
About CODI D/B/A Compass Diversified Holdings Shares of Beneficial Interest
Compass Diversified Holdings is a diversified business conglomerate based in the United States having two groups: branded consumer business and industrial business. Branded consumer businesses are characterized as those businesses that capitalize on a valuable brand name in their respective market sector. It includes 5.11, Ergobaby, Liberty Safe, and Velocity Outdoor. Industrial businesses are characterized as those businesses that focus on manufacturing and selling particular products and industrial services within a specific market sector. The company has operations in the United States, Canada, Europe, Asia Pacific, and other International areas.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.